Regeneron Pharma $REGN announced that a Phase 2 clinical study, CAPELLA, assessing EYLEA co-formulated with rinucumab, for the treatment of patients with neovascular age-related macular degeneration (wet AMD) fell short of showing a treatment benefit over EYLEA alone.